Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right? - CLL Society
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM
Frontiers | Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
Cancers | Free Full-Text | Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia - ScienceDirect
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma | Haematologica
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Rationale Objective Study Schema Treatment Plan Eligibility Criteria Rationale Follow Up
Venetoclax regimen not superior to standard therapy alone for older patients with CLL
J&J, AbbVie's Imbruvica pads CLL lead with FDA green light in younger patients | Fierce Pharma
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results | Blood Cancer Journal
Ibrutinib in Combination with Rituximab or Lenalidomide/Rituximab for Untreated FL | Research To Practice
Managing CLL With BTK Inhibitors - ppt download
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia -
A041202 Public Results Summary
Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug | OTT
Cancers | Free Full-Text | First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Ibrutinib Therapy for CLL: Long-Term Data
Ongoing or planned phase 3 trials in the first-line setting for CLL | Download Table
ALLIANCE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Jennifer A. Woyach: Results of Alliance North American Intergroup Study A041202 - YouTube
ADVANCES IN TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on - Molica - 2020 - Hematological Oncology - Wiley Online Library
